Considering that the most prominent complications associated with ICIs encompass chronic immune-related adverse events like dermatitis, hepatitis, arthritis, and colitis, and recognizing CHI3L1 as a significant immune checkpoint modulator, the concurrent targeting of CHI3L1 using bispecific antibodies may represent a prospective solution [148,149]. This evidence concerns the gene CHI3L1 and dermatitis.